Cargando…

Correction to: Fischer et al., Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2018
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011846/ https://www.ncbi.nlm.nih.gov/pubmed/29390895 http://dx.doi.org/10.1080/14756366.2018.1433261

Ejemplares similares

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance
por: Fischer, Tim, et al.
Publicado: (2017)

Tyrosine Kinase Inhibitors Regulate OPG through Inhibition of PDGFRβ
por: O’Sullivan, Susannah, et al.
Publicado: (2016)

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and IGF-1R
por: Hempel, Cornelius, et al.
Publicado: (2017)

The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma
por: Shroff, Rachna T, et al.
Publicado: (2018)

Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations
por: Hu, S, et al.
Publicado: (2017)

Targeted polypharmacology: Discovery of dual inhibitors of tyrosine and phosphoinositide kinases
por: Apsel, Beth, et al.
Publicado: (2008)

LRIG2 promotes the proliferation and cell cycle progression of glioblastoma cells in vitro and in vivo through enhancing PDGFRβ signaling
por: Xiao, Qungen, et al.
Publicado: (2019)

LRIG2 promotes the proliferation and cell cycle progression of glioblastoma cells in vitro and in vivo through enhancing PDGFRβ signaling
por: Xiao, Qungen, et al.
Publicado: (2022)

Cryptotanshinone inhibits IgE-mediated degranulation through inhibition of spleen tyrosine kinase and tyrosine-protein kinase phosphorylation in mast cells
por: Buyanravjikh, Sumiyasuren, et al.
Publicado: (2021)

The VEGFR/PDGFR tyrosine kinase inhibitor, ABT-869, blocks necroptosis by targeting RIPK1 kinase
por: Pierotti, Catia L., et al.
Publicado: (2023)

Tyrosine kinase inhibitor sensitive PDGFRΑ mutations in GIST: Two cases and review of the literature
por: Boonstra, Pieter A., et al.
Publicado: (2017)

Corrigendum to “Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications”
por: Quintanal-Villalonga, A., et al.
Publicado: (2018)

AXL and MET receptor tyrosine kinases are essential for lung cancer metastasis
por: Choi, Yun Jung, et al.
Publicado: (2019)

Antiproliferative effects of imatinib mesylate on ZR-75-1 and MDA-MB-231 cell lines via PDGFR-β, PDGF-BB, c-Kit and SCF expression
por: Kadivar, Ali, et al.
Publicado: (2019)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
por: Huang, Lihua, et al.
Publicado: (2015)

Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors
por: Amelia, Tasia, et al.
Publicado: (2022)

AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and anti-tumour activity via targeting VEGFR, FGFR and PDGFR
por: Zhou, Yuanfeng, et al.
Publicado: (2012)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
por: Xu, Haiyuan, et al.
Publicado: (2019)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
por: Makhlin, Igor, et al.
Publicado: (2019)

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations
por: Suda, Kenichi, et al.
Publicado: (2021)

Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models
por: Lubet, Ronald A., et al.
Publicado: (2019)

Marine Derived Hamacanthins as Lead for the Development of Novel PDGFRβ Protein Kinase Inhibitors
por: Pinchuk, Boris, et al.
Publicado: (2013)

Comparison of Immunogen Designs That Optimize Peptide Coverage: Reply to Fischer et al
por: Nickle, David C, et al.
Publicado: (2008)

Corrigendum: Glycogen synthase kinase-3β inhibitor SB216763 promotes DNA repair in ischemic retinal neurons
Publicado: (2021)

Fatty Acid Synthase Inhibitor G28 Shows Anticancer Activity in EGFR Tyrosine Kinase Inhibitor Resistant Lung Adenocarcinoma Models
por: Polonio-Alcalá, Emma, et al.
Publicado: (2020)

Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?
por: Massard, C, et al.
Publicado: (2008)

Clinical significance of Janus Kinase inhibitor selectivity
por: Choy, Ernest H
Publicado: (2019)

Anticancer Effect of Fucoidan in Combination with Tyrosine Kinase Inhibitor Lapatinib
por: Oh, Byeongsang, et al.
Publicado: (2014)

Corrigendum: Caenorhabditis Intervention Testing Program: the tyrosine kinase inhibitor imatinib mesylate does not extend lifespan in nematodes. microPublication Biology July 3, 2019. 10.17912/micropub.biology.000131
Publicado: (2019)

NLRP3 tyrosine phosphorylation is controlled by protein tyrosine phosphatase PTPN22
por: Spalinger, Marianne R., et al.
Publicado: (2023)

Optimization of Substituted 6-Salicyl-4-Anilinoquinazoline Derivatives as Dual EGFR/HER2 Tyrosine Kinase Inhibitors
por: Li, Dong-Dong, et al.
Publicado: (2013)

Correction to: Abhishek et al., Antioxidant and anti-inflammatory activities of Aerva pseudotomentosa leaves
Publicado: (2017)

Correction to Yang T, et al. Chin Med J 2022;135:672-680.
Publicado: (2022)

Correction: Comparison of Immunogen Designs That Optimize Peptide Coverage: Reply to Fischer et al
por: Nickle, David C, et al.
Publicado: (2008)

Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2
por: Kim, Hwang-Phill, et al.
Publicado: (2009)

Correction to: Shu, et al., HIV/AIDS-related hyponatremia: an old but still serious problem
Publicado: (2018)

Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial
por: Song, Yan, et al.
Publicado: (2021)

Radiofrequency Ablation with Continued EGFR Tyrosine Kinase Inhibitor Therapy Prolongs Disease Control in EGFR-Mutant Advanced Lung Cancers with Acquired Resistance to EGFR Tyrosine Kinase Inhibitors: Two Case Reports
por: Shi, Xuefei, et al.
Publicado: (2020)

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
por: Baldacci, Simon, et al.
Publicado: (2017)

Chronicles of EGFR Tyrosine Kinase Inhibitors: Targeting EGFR C797S Containing Triple Mutations
por: Duggirala, Krishna Babu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9at92bdntkhc4u7bb3g5nu7h9l